Evogene Ltd [NASDAQ: EVGN] gained 0.64% on the last trading session, reaching $1.58 price per share at the time.
Evogene Ltd represents 6.67 million in outstanding shares, while the company has a total market value of $10.55 million with the latest information. EVGN stock price has been found in the range of $1.52 to $1.62.
If compared to the average trading volume of 2.08M shares, EVGN reached a trading volume of 176669 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Evogene Ltd [EVGN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EVGN shares is $3.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EVGN stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
ROTH Capital have made an estimate for Evogene Ltd shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 08, 2021. While these analysts kept the previous recommendation, Aegis Capital raised their target price to Buy. The new note on the price target was released on July 29, 2021, representing the official price target for Evogene Ltd stock. Previously, the target price had yet another raise to $9, while Cantor Fitzgerald analysts kept a Overweight rating on EVGN stock.
The Average True Range (ATR) for Evogene Ltd is set at 0.19, with the Price to Sales ratio for EVGN stock in the period of the last 12 months amounting to 1.56.
Trading performance analysis for EVGN stock
Evogene Ltd [EVGN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -12.71. With this latest performance, EVGN shares gained by 17.91% in over the last four-week period, additionally plugging by 15.33% over the last 6 months – not to mention a drop of -76.04% in the past year of trading.
Evogene Ltd [EVGN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Evogene Ltd [EVGN] shares currently have an operating margin of -331.65% and a Gross Margin at 5.41%. Evogene Ltd’s Net Margin is presently recorded at -224.82%.
Return on Equity for this stock declined to -37.51%, with Return on Assets sitting at -37.51%.
Evogene Ltd [EVGN]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EVGN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Evogene Ltd go to 29.80%.
An analysis of Institutional ownership at Evogene Ltd [EVGN]
There are presently around $6.46%, or 6.55%% of EVGN stock, in the hands of institutional investors. The top three institutional holders of EVGN stocks are: SILVERARC CAPITAL MANAGEMENT, LLC with ownership of 3.08 million shares, which is approximately 6.0837%. MORGAN STANLEY, holding 0.22 million shares of the stock with an approximate value of $$0.14 million in EVGN stocks shares; and MORGAN STANLEY, currently with $$65294.0 in EVGN stock with ownership which is approximately 0.1983%.
